Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/27703
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKelly, Richard-
dc.contributor.authorAnton, Angelyn-
dc.contributor.authorWong, Shirley-
dc.contributor.authorShapiro, Julia-
dc.contributor.authorWeickhardt, Andrew J-
dc.contributor.authorAzad, Arun-
dc.contributor.authorKwan, Edmond Michael-
dc.contributor.authorSpain, Lavinia-
dc.contributor.authorMuthusamy, Arun-
dc.contributor.authorTorres, Javier-
dc.contributor.authorParente, Phillip-
dc.contributor.authorParnis, Francis-
dc.contributor.authorGoh, Jeffrey-
dc.contributor.authorJoshua, Anthony-
dc.contributor.authorPook, David-
dc.contributor.authorBaenziger, Olivia-
dc.contributor.authorGibbs, Peter-
dc.contributor.authorTran, Ben-
dc.date.accessioned2021-10-11T04:12:38Z-
dc.date.available2021-10-11T04:12:38Z-
dc.date.issued2021-10-
dc.identifier.citationBJU International 2021; 128 Suppl 1: 18-26en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/27703-
dc.description.abstractTo investigate the recent real-world use of first-generation antiandrogens (FGAs) in metastatic castration-resistant prostate cancer (mCRPC) using a retrospective multicentre cohort study. The electronic CRPC Australian Database (ePAD) was interrogated to identify patients with mCRPC. Clinicopathological features, treatment and outcome data, stratified by FGA use, were retrieved and reported through descriptive statistics. Survival analyses were calculated using the Kaplan-Meier method and groups compared using log-rank tests. Factors influencing overall survival (OS) were analysed using Cox proportional hazards regression model. We identified 634 patients with mCRPC, enrolled in ePAD between January 2016 and March 2019, including 322 (51%) who received FGAs. The median follow-up was 21.9 months. Patients treated with FGAs were more likely to have lower International Society of Urological Pathologists (ISUP) grade group (P = 0.04), longer median time to CRPC (25.6 vs 16.0 months, P < 0.001), and were less likely to have visceral metastases (5.0% vs 11.2%, P = 0.005) or to have received upfront docetaxel (P < 0.001). A ≥50% reduction from pre-treatment prostate-specific antigen (PSA) level (PSA50 response) during FGA treatment occurred in 119 (37%) patients and was independently associated with improved OS (hazard ratio 0.233, P < 0.001). Prior FGA treatment did not significantly influence the selection of subsequent life-prolonging treatments for mCRPC or their PSA50 response rates. In our present cohort, FGAs were commonly used in lower-risk mCRPC and their use did not significantly influence the choice or duration of subsequent systemic therapy. A PSA50 response to FGA therapy was an independent favourable prognostic marker associated with improved OS.en
dc.language.isoeng-
dc.subject#PCSMen
dc.subject#ProstateCanceren
dc.subject#urooncen
dc.subjectfirst-generation antiandrogenen
dc.subjectprostate canceren
dc.subjectreal-world dataen
dc.titleReal-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer.en
dc.typeJournal Articleen
dc.identifier.journaltitleBJU Internationalen
dc.identifier.affiliationEastern Health, Melbourne, Vic., Australiaen
dc.identifier.affiliationAlfred Health, Melbourne, Vic., Australiaen
dc.identifier.affiliationWestern Health, Melbourne, Vic., Australiaen
dc.identifier.affiliationPeter MacCallum Cancer Centre, Melbourne, Vic., Australiaen
dc.identifier.affiliationSt Vincent's Hospital, Sydney, NSW, Australiaen
dc.identifier.affiliationRoyal Brisbane and Women's Hospital, Brisbane, Qld, Australiaen
dc.identifier.affiliationUniversity of Adelaide, Adelaide, SA, Australiaen
dc.identifier.affiliationGoulburn Valley Health, Shepparton, Vic., Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Wellness and Research Centreen
dc.identifier.affiliationMonash University, Melbourne, Vic., Australiaen
dc.identifier.affiliationMonash Health, Melbourne, Vic., Australiaen
dc.identifier.affiliationWalter and Eliza Hall Institute, Melbourne, Vic., Australiaen
dc.identifier.affiliationAdelaide Cancer Centre, Adelaide, SA, Australiaen
dc.identifier.doi10.1111/bju.15364en
dc.type.contentTexten
dc.identifier.orcid0000-0002-8459-7961en
dc.identifier.orcid0000-0001-7350-5622en
dc.identifier.pubmedid34622543-
local.name.researcherWeickhardt, Andrew J
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

40
checked on Dec 26, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.